Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015131 | 0.89 | CYP1A2 (0.61) | CYP1A2CYP2C9MEN1KMT2ATSHR | |
| SCHEMBL721934 | 0.89 | CYP1A2 (0.58) | CYP1A2CYP2C9TSHRPKMNPC1 | |
| SCHEMBL11217225 | 0.89 | CYP1A2 (0.58) | CYP1A2CYP2C9MEN1KMT2ATSHR | |
| P-Xylene SCHEMBL3752326 | 0.87 | CYP1A2 (0.70) | CYP1A2CYP2C9POLBTSHRTP53 | |
| SCHEMBL3459786 | 0.86 | CYP1A2 (0.65) | CYP1A2CYP2C9MEN1KMT2APOLB | |
| SCHEMBL19433083 | 0.86 | CYP1A2 (0.59) | CYP1A2CYP2C9MEN1KMT2ATSHR | |
| SCHEMBL7135046 | 0.86 | CYP1A2 (0.54) | CYP1A2CYP2C9MEN1KMT2APOLB | |
| SCHEMBL335424 | 0.85 | CYP1A2 (0.61) | CYP1A2CYP2C9MEN1KMT2APOLB | |
| SCHEMBL2729317 | 0.84 | CYP1A2 (0.80) | CYP1A2CYP2C9TSHRPKMALDH1A1 | |
| Sulfuric Acid SCHEMBL31183034 | 0.84 | CYP1A2 (0.84) | CYP1A2CYP2C9TSHRCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| WO-2005117932-A1 | BISUBSTRATE INHIBITORS OF PROTEIN TYROSINE KINASES AS THERAPEUTIC AGENTS | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-0970100-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035977-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | NR2E3, NR4A1, NR4A3 | CYP1A2 99/4885CYP2C9 398/4885MEN1 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.